Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

Over the last 7 days, the United States market has dropped 2.7%, but it has shown resilience with an 11% rise over the past year and earnings forecasted to grow by 14% annually. In this context, ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals (NASDAQ:VRTX) ended a four-day winning streak on Thursday after UnitedHealth (NYSE:UNH) placed its new ...